News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Brian Ellman, MBA

Articles by Brian Ellman, MBA

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy

ByGirishanthy Krishnarajah, MPH, MBA/MS, PhD,Jee-Yeon K. Lehmann, PhD,Brian Ellman, MBA,Rachel H. Bhak, MS,Maral DerSarkissian, PhD,Deane Leader, Jr, PhD, MBA,Ann L. Bullinger, PharmD,Mei

October 21st 2016

Latest Updated Articles

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
Published: October 21st 2016 | Updated:

Trending on AJMC

Behind the Scenes of Multiple Myeloma Care: A Pharmacist’s View With Kelley L. Julian, PharmD, BCOP

AI–Enhanced SALT Score Improves Accuracy in Alopecia Areata Assessment

A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform

Frequent Dining Out Linked to Higher Colorectal Cancer Risk

White House to Announce Second Drug Pricing Deal as AstraZeneca Joins TrumpRx

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.